Dr. Efstathiou on the rPFS Benefit Achieved With Apalutamide Regimen in mCRPC
February 12th 2021
Eleni Efstathiou, MD, discusses the key findings of the placebo-controlled, double-blind phase 3 ACIS study of apalutamide and abiraterone acetate plus prednisone versus prednisone alone in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer.